These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 11524494)

  • 21. Glatiramer acetate (Copaxone) therapy for multiple sclerosis.
    Dhib-Jalbut S
    Pharmacol Ther; 2003 May; 98(2):245-55. PubMed ID: 12725872
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Remitting Multiple Sclerosis.
    Zivadinov R; Dwyer MG; Ramasamy DP; Davis MD; Steinerman JR; Khan O
    J Neuroimaging; 2015; 25(6):989-95. PubMed ID: 26394270
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An MRI-defined measure of cerebral lesion severity to assess therapeutic effects in multiple sclerosis.
    Kim G; Tauhid S; Dupuy SL; Tummala S; Khalid F; Healy BC; Bakshi R
    J Neurol; 2016 Mar; 263(3):531-8. PubMed ID: 26754005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome.
    Comi G; Martinelli V; Rodegher M; Moiola L; Leocani L; Bajenaru O; Carra A; Elovaara I; Fazekas F; Hartung HP; Hillert J; King J; Komoly S; Lubetzki C; Montalban X; Myhr KM; Preziosa P; Ravnborg M; Rieckmann P; Rocca MA; Wynn D; Young C; Filippi M
    Mult Scler; 2013 Jul; 19(8):1074-83. PubMed ID: 23234810
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dendritic cell, monocyte and T cell activation and response to glatiramer acetate in multiple sclerosis.
    Sellebjerg F; Hesse D; Limborg S; Lund H; Søndergaard HB; Krakauer M; Sørensen PS
    Mult Scler; 2013 Feb; 19(2):179-87. PubMed ID: 22653658
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab.
    Rossi S; Motta C; Studer V; De Chiara V; Barbieri F; Monteleone F; Fornasiero A; Coarelli G; Bernardi G; Cutter G; Stüve O; Salvetti M; Centonze D
    Eur J Neurol; 2013 Jan; 20(1):87-94. PubMed ID: 22741530
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.
    Cadavid D; Wolansky LJ; Skurnick J; Lincoln J; Cheriyan J; Szczepanowski K; Kamin SS; Pachner AR; Halper J; Cook SD
    Neurology; 2009 Jun; 72(23):1976-83. PubMed ID: 19279320
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of standard 1.5 T vs. 3 T optimized protocols in patients treated with glatiramer acetate. A serial MRI pilot study.
    Zivadinov R; Hojnacki D; Hussein S; Bergsland N; Carl E; Durfee J; Dwyer MG; Kennedy C; Weinstock-Guttman B
    Int J Mol Sci; 2012; 13(5):5659-5673. PubMed ID: 22754322
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent insights into the mechanism of action of glatiramer acetate.
    Kala M; Miravalle A; Vollmer T
    J Neuroimmunol; 2011 Jun; 235(1-2):9-17. PubMed ID: 21402415
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term therapy with glatiramer acetate in multiple sclerosis: effect on T-cells.
    Ragheb S; Abramczyk S; Lisak D; Lisak R
    Mult Scler; 2001 Feb; 7(1):43-7. PubMed ID: 11321193
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of glatiramer acetate on MS lesions enhancing at different gadolinium doses.
    Rovaris M; Codella M; Moiola L; Ghezzi A; Zaffaroni M; Mancardi G; Capello E; Sardanelli F; Comi G; Filippi M
    Neurology; 2002 Nov; 59(9):1429-32. PubMed ID: 12427898
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Copolymer-1 in the treatment of multiple sclerosis.
    Boyden KM
    J Neurosci Nurs; 1998 Apr; 30(2):135-9; quiz 140-1. PubMed ID: 9642622
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial.
    Metz LM; Li D; Traboulsee A; Myles ML; Duquette P; Godin J; Constantin M; Yong VW;
    Mult Scler; 2009 Oct; 15(10):1183-94. PubMed ID: 19776092
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study.
    Khan O; Rieckmann P; Boyko A; Selmaj K; Ashtamker N; Davis MD; Kolodny S; Zivadinov R
    Mult Scler; 2017 May; 23(6):818-829. PubMed ID: 27503905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative studies of glatiramer acetate and interferon beta.
    Goodin D
    Int MS J; 2008 Jun; 15(2):39-41. PubMed ID: 18782497
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Spotlight on glatiramer acetate in relapsing-remitting multiple sclerosis.
    Simpson D; Noble S; Perry C
    BioDrugs; 2003; 17(3):207-10. PubMed ID: 12749757
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis.
    Simpson D; Noble S; Perry C
    CNS Drugs; 2002; 16(12):825-50. PubMed ID: 12421116
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis.
    Sormani MP; Rovaris M; Valsasina P; Wolinsky JS; Comi G; Filippi M
    Neurology; 2004 Apr; 62(8):1432-4. PubMed ID: 15111692
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiple sclerosis: expression of CD1a and production of IL-12p70 and IFN-gamma by blood mononuclear cells in patients on combination therapy with IFN-beta and glatiramer acetate compared to monotherapy with IFN-beta.
    Hussien Y; Sanna A; Söderström M; Link H; Huang YM
    Mult Scler; 2004 Feb; 10(1):16-25. PubMed ID: 14760948
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications.
    Rovaris M; Comi G; Rocca MA; Wolinsky JS; Filippi M;
    Brain; 2001 Sep; 124(Pt 9):1803-12. PubMed ID: 11522582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.